期刊文献+

熊果酸氨基酸偶联物的合成及保肝活性 被引量:1

Synthesis and hepatoprotective activity of three amino acid conjugates of ursolic acid
原文传递
导出
摘要 目的设计合成熊果酸28位氨基酸偶联物并测定其保肝活性。方法以熊果酸为起始原料,首先将3位羟基进行酯保护2,8位羧基与保护的氨基酸反应,然后脱保护基,得到偶联物。利用肝细胞培养和小鼠急性肝损伤CCl4、ConA筛选模型分别测定偶联物的体外、体内保肝活性。结果与结论得到3个未见报道的化合物,其结构经核磁共振谱和质谱确定。水溶性测定结果显示3个偶联物的水溶性很低,保肝试验结果显示3个偶联物无明显的保肝活性。 Ursolic acid is a pentacyclic triterpenoid showing anticancer,anti-virus,anti-inflammatory,hepatoprotective and anti-microbial activities.In order to improve its water solubility so as to enhance its bioavailability,three amino acid conjugates of ursolic acid were designed and synthesized.Starting from ursolic acid,its 3-OH was protected by esterification first,and then 28-COOH reacted with the protected amino acid reagents.After deprotection,three targeted compounds,5a,5b and 5c,were obtained.These new compounds were characterized by various spectroscopic methods,including 1H-NMR,13C-NMR and ESI-MS.The in vitro and in vivo hepatoprotective activity was measured in GalN inducing hepatocyte injury model,and CCl4 and ConA inducing hepatocyte injury model,respectively.No apparent hepatoprotective activities were detected in both models.
出处 《中国药物化学杂志》 CAS CSCD 2011年第3期232-235,共4页 Chinese Journal of Medicinal Chemistry
基金 “重大新药创制”科技重大专项综合大平台项目(2009ZX09301-003-4-1)
关键词 熊果酸 保肝活性 前药 ursolic acid hepatoprotective activity pre-drug
  • 相关文献

参考文献14

  • 1CHIANG L C,CHIANG W,CHANG M Y,et al.Antileukemic activity of selected natural products in Taiwan[J].Am J Chin Med,2003,31(1): 37-46.
  • 2SOHN K H,LEE H Y,CHUNG H Y,et al.Antiangiogenic activity of triterpene acids[J].Cancer Lett,1995,94(2): 213-218.
  • 3KASHIWADA Y,WANG H K,NAGAO T,et al.Anti-AIDS agents.30.Anti-HIV activity of oleanolic acid,pomolic acid,and structurally related triterpenoids[J].J Nat Prod,1998,61(9): 1090-1095.
  • 4ISMAILI H,SOSA S,BRKIC D,et al.Topical anti-inflammatory activity of extracts and compounds from Thymus broussonettii[J].J Pharm Pharmacol,2002,54(8): 1137-1140.
  • 5ISMAILI H,TORTORA S,SOSA S,et al.Topical anti-inflammatory activity of Thymus willdenowii[J].J Pharm Pharmacol,2001,53(12): 1645-1652.
  • 6BARICEIVIC D,SOSA S,DELLA L R,et al.Topical anti-inflammatory activity of Salvia officinalis L.leaves: the relevance of ursolic acid[J].J Ethnopharmacol,2001,75(2/3): 125-132.
  • 7SHUKLA B,VISEN P K S,PATNAIK G K,et al.Hepatoprotective activity in the rat of ursolic acid isolated from Eucalyptus hybrid[J].Phytother Res,2006,6(2): 74-79.
  • 8MARTIN-ARAGON S,deLAS HERAS B,SANCHEZ-REUS M I,et al.Pharmacological modification of endogenous antioxidant enzymes by ursolic acid on tetrachloride- induced liver damage in rats and primary cultures of rat hepatocytes[J].Exp Toxicol Pathol,2001,53(2/3): 199-206.
  • 9熊筱娟,陈武,肖小华,徐丽英,崔江龙.乌索酸与齐墩果酸对小鼠实验性肝损伤保护作用的比较[J].江西师范大学学报(自然科学版),2004,28(6):540-543. 被引量:30
  • 10SARASWAT B,VISEN P K S,DAYAL R,et al.Protective action of ursolic acid against chemical induced hepato-toxicity in rats[J].Indian J Pharmacol,1996,28( 4): 232-239.

二级参考文献22

  • 1张乐之,李新芳.齐墩果酸对大鼠实验性肝损伤作用机理的研究[J].中药药理与临床,1992,8(2):24-26. 被引量:35
  • 2张均田.现代药理学实验方法[M].北京医科大学中国协和医科大学联合出版社,1998.739.
  • 3任冬梅,袁久荣.岩青兰化学成分的研究[J].中草药,1997,28(2):74-76. 被引量:22
  • 4李开泉.陆英抗肝炎主要活性成分乌索酸的化学研究[J].中草药,2001,32:36-37.
  • 5<全国中草药汇编>编写组.全国中草药汇编(上册)[M].北京:人民卫生出版社,1983.
  • 6Liu J. Pharmacology of oleanolic acid and ursolic acid[ J ]. Journal of Ethnopharamacology, 1995,49: 57 - 68.
  • 7Balanehru S Nagarajan B. Protectine effectof okeanloic acid and Ursolic acid aganist Lopid Peroxidation[J]. Biocheni Int, 1991,24(5):981.
  • 8许强.乌苏酸提取方法介绍[J]中国中药杂志,1989(03).
  • 9何心亮,王风云,吴维群.山楂中熊果酸的分离提取及含量测定[J]中成药,1988(08).
  • 10马学惠,赵元昌,尹镭,徐瑞龄,韩德五,王明时.乌苏酸对实验性肝损伤的防治作用[J]药学学报,1986(05).

共引文献74

同被引文献22

  • 1熊筱娟,陈武,肖小华,徐丽英,崔江龙.乌索酸与齐墩果酸对小鼠实验性肝损伤保护作用的比较[J].江西师范大学学报(自然科学版),2004,28(6):540-543. 被引量:30
  • 2Chiang L. C.,Chiang W.,Chang M. Y.,Ng L. T. Lin C. C.,Am. J. Chin. Med. , 2003 , 3i(l), 37-46.
  • 3Sohn K. H.,Lee H. Y.,Chung H. Y.,Young H. S.,Yi S. Y.,Cancer Lett.,1995, 94(2),213-218.
  • 4Kashiwada Y.,Wang H. K.,Nagao T.,Kitanaka S.,Yasuda I.,Fujioka T.,Yamagishi T. , Cosentino L. M.,Kozuka M.,OkabeH.,Ikeshiro Y.,Hu C. Q. , Yeh E.,Lee K. H.,J. Nat. Prod.,1998, 61(9), 1090-1095.
  • 5Ismaili H.,Sosa S.,Brkic D. , Fkih-Tetouani S.,Ilidrissi A.,Touati D.,Aquino R. P.,Tubaro A.,J. Pharm. PharmacoL,2002,5^(8), 1137-1140.
  • 6Ismaili H. , Tortora S.,Sosa S.,Fkih-Tetouani S.,Iiidrissi A.,Della L. R.,Tubaro A.,Aquino R.,J. Pharm. PharmacoL,2001,55(12), 1645-1652.
  • 7Bariceivic D.,Sosa S.,Della L. R.,Tubaro A.,Simonovska B.,Krasna A.,Zupancic A.,J. Ethnopharmacol.,2001,75(2/3),125-132.
  • 8Shukla B.,Visen P. K. S.,Patnaik G. K.,Tripathi S. C.,Srimal R. C. , Dayal R.,Dobhal P. C.,Pkytotker. Res.,2006, 6(2),74-79.
  • 9Martin-Aragon S.,de las Heras B.,Sanchez-reus M. I.,Benedi J,,Exp. Toxicol. Pathol.,2001, 53 (2/3 ) , 199206.
  • 10Wang S. P.,Lai J. S.,Huang K. F.,Chin. Pharm. J. , 1993 , 45(4),329-336.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部